Using Decipher Genomic Classifier in diagnosis of Prostate Cancer

Posted by waynen @waynen, Mar 5 10:04am

For men facing diagnosis of prostate cancer this study might be helpful.

This systematic review evaluated the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). A total of 42 studies and more than 30,000 patients were included. The authors found that GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) in 24 studies.

The authors provide consistent evidence that this test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision–making. The utility of the GC is strongest for intermediate-risk prostate cancer and post-prostatectomy decision–making.
– Gautam Jayram, MD

Here is a link to the abstract of the study. You have to pay to see the full journal article.
– A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/33293078/

A reliable identifier of which cancers are more or less agressive is a welcome tool in making treatment decisions for men diagnosed with prostate cancer!

REPLY
Please sign in or register to post a reply.
  Request Appointment